Analyst Joon Lee of Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report), with a price target of $150.00.
Joon Lee has given his Buy rating due to a combination of factors that highlight Corcept Therapeutics’ promising future prospects. The company recently reported positive Phase 3 ROSELLA trial results for its ovarian cancer treatment, showing competitive progression-free survival and overall survival rates compared to existing treatments. This positions the company well for a New Drug Application submission in the third quarter of 2025, with potential approval and market launch anticipated around 2026 or 2027.
Additionally, the treatment’s oral formulation and broader applicability, regardless of folate receptor status, provide a commercial advantage over competitors. The long-term intellectual property protection extending into the 2040s further strengthens the company’s position. With these factors in mind, Joon Lee has increased the price target for Corcept Therapeutics to $150, reflecting confidence in the company’s growth potential and market opportunities.
According to TipRanks, Lee is a 5-star analyst with an average return of 19.2% and a 47.63% success rate. Lee covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Viking Therapeutics, and Solid Biosciences.
In another report released on March 28, Citi also maintained a Buy rating on the stock with a $150.00 price target.